IDEAYA Biosciences, Inc. (IDYA) Surges 7.6%: Is This an Indication of Further Gains?Zacks Investment Research • 10/18/23
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal MelanomaPRNewsWire • 10/17/23
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous MelanomaPRNewsWire • 10/16/23
IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D DayPRNewsWire • 10/09/23
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast CancerPRNewsWire • 09/27/23
IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 MutationsPRNewsWire • 09/26/23
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid TumorsPRNewsWire • 09/11/23
IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations EventsPRNewsWire • 09/05/23
IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)PRNewsWire • 08/21/23
IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal MelanomaPRNewsWire • 08/16/23
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/23
IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 08/10/23
IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) TumorsPRNewsWire • 08/02/23
IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations EventPRNewsWire • 08/01/23
IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib MonotherapyPRNewsWire • 06/22/23
IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor TypesPRNewsWire • 06/12/23
IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations EventsPRNewsWire • 05/30/23
Goldman Sachs Initiates Coverage of Ideaya Biosciences With Buy Recommendation24/7 Wall Street • 05/25/23
IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid TumorsPRNewsWire • 05/22/23
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal MelanomaPRNewsWire • 05/16/23
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/09/23
IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 05/09/23